The DOI matches its Crossref record; its reference list is not available; 5 of the 32 sources its claims cite were checked for support.
The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis
Open accessAbstract
Purpose: About 20–25% of patients experience weight regain (WR) or insufficient weight loss (IWL) after bariatric metabolic surgery (BS). Therefore, we aimed to retrospectively assess the effectiveness of adjunct treatment with the GLP-1 receptor agonist semaglutide in non-diabetic patients with WR or IWL after BS. Materials and Methods: Post-bariatric patients without type 2 diabetes (T2D) with WR or IWL (n = 44) were included in the analysis. The primary endpoint was weight loss 3 and 6 months after initiation of adjunct treatment. Secondary endpoints included change in BMI, HbA1c, lipid profile, hs-CRP, and liver enzymes. Results: Patients started semaglutide 64.7 ± 47.6 months (mean ± SD) after BS. At initiation of semaglutide, WR after post-bariatric weight nadir was 12.3 ± 14.4% (mean ± SD). Total weight loss during semaglutide treatment was − 6.0 ± 4.3% (mean ± SD, p < 0.001) after 3 months (3.2 months, IQR 3.0–3.5, n = 38) and − 10.3 ± 5.5% (mean ± SD, p < 0.001) after 6 months (5.8 months, IQR 5.8–6.4, n = 20). At 3 months, categorical weight loss was > 5% in 61% of patients, > 10% in 16% of patients, and > 15% in 2% of patients. Triglycerides (OR = 0.99; p < 0.05), ALT (OR = 0.87; p = 0.05), and AST (OR = 0.89; p < 0.05) at baseline were negatively associated with weight loss of at least 5% at 3 months’ follow-up (p < 0.05). Conclusion: Treatment options to manage post-bariatric excess weight (regain) are scarce. Our results imply a clear benefit of adjunct treatment with semaglutide in post-bariatric patients. However, these results need to be confirmed in a prospective randomized controlled trial to close the gap between lifestyle intervention and revision surgery in patients with IWL or WR after BS. Graphical abstract:
Overview
CoChat Summary
TL;DR
In non-diabetic patients with weight regain or insufficient weight loss after bariatric surgery, adjunct semaglutide 0.5 mg once-weekly was associated with significant weight loss at 3 and 6 months. The authors conclude this implies a clear benefit but state results need confirmation in a prospective randomized controlled trial.
Key findings
- Among 44 patients, semaglutide was started 64.7 ± 47.6 months after bariatric surgery; weight regain after post-bariatric nadir was 12.3 ± 14.4%. Total weight loss was −6.0 ± 4.3% at 3 months (n = 38, p < 0.001) and −10.3 ± 5.5% at 6 months (n = 20, p < 0.001).
- At 3 months, categorical weight loss was >5% in 61%, >10% in 16%, and >15% in 2% of patients; at 6 months, >5% in 85%, >10% in 45%, and >15% in 5%.
- No significant differences in weight loss were found between SG and RYGB at 3 months (p = 0.7) or 6 months (p = 0.8), or between WR and IWL groups. Female patients had greater weight loss at 3 months (−7.10 ± 3.95%) than male patients (−2.44 ± 3.77%; p = 0.005).
- Baseline triglycerides (OR = 0.99; p < 0.05), ALT (OR = 0.87; p = 0.05), and AST (OR = 0.89; p < 0.05) were negatively associated with ≥5% weight loss at 3 months. HbA1c, lipids, hs-CRP, and liver enzymes showed no significant change; side effects included nausea in two patients during the first 2 weeks and one transient lipase increase.
Methods
- Retrospective analysis of 44 adult non-diabetic post-bariatric patients with WR or IWL after SG or RYGB, treated between 2020 and 2022 at a certified obesity outpatient clinic; 9 of 53 initial patients were excluded.
- Patients received semaglutide 0.25 mg/week for the first 4 weeks, then 0.5 mg/week thereafter according to tolerability; data were allocated to baseline, 1 month (n = 44), 3 months (n = 38), and 6 months (n = 20).
- Analyses included descriptive statistics, Student’s t-test, chi-square, one-way ANOVA with Dunnett’s test, two-way ANOVA with Šídák’s test, and univariate logistic regression for ≥5% weight loss at 3 months; p < 0.05 was significant.
Limitations
- The paper states this was a retrospective analysis of a small number of patients lacking a control group, with only 20 patients at 6 months’ follow-up, and that differences in dose titration and time point of treatment initiation may have impacted variability in weight loss.
- Evident from the text: it was a single-center observational study using off-label semaglutide at a maximum dose of 0.5 mg once-weekly, so causality cannot be established and results may not generalize to the later-approved 2.4 mg dose.
- Evident from the text: some subgroup results, including sex differences and WR versus IWL comparisons, are reported as “data not shown.”
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
4 Valid · 0 Not valid · 14 Not checked · 39 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Approximately 20–25% of patients experience considerable weight regain (WR) defined as regain of weight that occurs after achievement of an initial successful weight loss (defined as EWL% > 50%) or insufficient weight loss (IWL) defined as < 50% EWL at 18 months after BS [2, 3].”
§ The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis > Introduction/Purpose
What the sources say
- Partly supportedcites [2] El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review. Obes Surg [Internet]. Obes Surg; 2021 [cited 2021 Sep 4];31:1755–66. Available from: https://pubmed.ncbi.nlm.nih.gov/33555451/ sourceExperimental — accuracy not yet measured
Our copy supports the definitional half of the sentence exactly: the 'Definition/s of WR and IWL after BS' section states IWL as EWL% < 50% at 18 months post-BS and WR as progressive regain after an initial successful weight loss (EWL > 50%). It does not support the 20–25% prevalence figure: the 'What Is the Reported Prevalence of WR and IWL After BS?' section gives only procedure-specific, heterogeneous estimates (38% of maximal weight lost regained 10 years after LAGB; 27.8%, range 14–37%, ≥7 years after LSG; 3.9% at 3–7 years after RYGB in LABS; 44–87% or 16–37% five years post-surgery depending on the measure used; IWL cited only as 40% and 32% of revisional-surgery indications), and the review stresses the lack of standardized definitions and that prevalence estimates vary accordingly. No passage in our copy states a combined 20–25% figure for WR or IWL, so that attributed number is unsupported. (LLM, conf=0.78)
- Not checked yetcites [3] Nedelcu M, Khwaja HA, Rogula TG. Weight regain after bariatric surgery-how should it be defined? Surg Obes Relat Dis [Internet]. Surg Obes Relat Dis; 2016 [cited 2021 Sep 5];12:1129–30. Available from: https://pubmed.ncbi.nlm.nih.gov/27350180/ source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the Swedish Obese Subjects (SOS) study, the first long-term prospective trial to provide information on the effects of BS, 10% of RYGB patients did not maintain ≥ 5% weight loss at 10-year follow-up [1, 5, 6].”
§ The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis > Introduction/Purpose
What the sources say
- Not checked yetcites [1] Kalarchian M, Turk M, Elliott J, et al. Lifestyle management for enhancing outcomes after bariatric surgery. Curr Diabetes Reports 2014 1410 [Internet]. Springer; 2014 [cited 2021 Sep 4];14:1–9. Available from: https://link.springer.com/article/https://doi.org/10.1007/s11892-014-0540-y source
- Supportedcites [5] Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med [Internet]. 2004;351:2683–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15616203 source
The Changes in Weight section reports that 8.8% of gastric-bypass patients who completed 10 years of the SOS study had lost less than 5% of their initial weight. The citing sentence rounds this to 10%; the result applies to 10-year completers. (LLM, conf=0.93)
- Partly supportedcites [6] Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish Obese Subjects. http://dx.doi.org/ [Internet]. Massachusetts Medical Society ; 2009 [cited 2021 Sep 5];357:741–52. Available from: https://www.nejm.org/doi/full/https://doi.org/10.1056/nejmoa066254 sourceExperimental — accuracy not yet measured
The Weight Change section reports that gastric-bypass patients had a mean weight loss of 25±11% at 10 years. It does not report the proportion of patients who failed to maintain at least 5% weight loss, so the claimed 10% cannot be verified from this paper. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, there are no approved weight management drugs for use in patients who had BS, even though several studies have suggested that the combination of pharmacotherapy and lifestyle modification results in more weight loss than either approach used alone [1, 12, 13].”
§ The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis > Introduction/Purpose
What the sources say
- Not checked yetcites [1] Kalarchian M, Turk M, Elliott J, et al. Lifestyle management for enhancing outcomes after bariatric surgery. Curr Diabetes Reports 2014 1410 [Internet]. Springer; 2014 [cited 2021 Sep 4];14:1–9. Available from: https://link.springer.com/article/https://doi.org/10.1007/s11892-014-0540-y source
- Supportedcites [12] Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med [Internet]. N Engl J Med; 2005 [cited 2021 Sep 4];353:2111–20. Available from: https://pubmed.ncbi.nlm.nih.gov/16291981/ source
The citation supports the sentence’s claim about combining treatments, not its separate statement about drug approval after bariatric surgery (BS). The Abstract reports that combined medication and group lifestyle modification produced more weight loss than either treatment alone in the trial’s obese adults. (LLM, conf=0.93)
- Not checked yetcites [13] Berkovitz RI, Wadden TA, Tershakovec AM, et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA [Internet]. JAMA; 2003 [cited 2021 Sep 4];289:1805–12. Available from: https://pubmed.ncbi.nlm.nih.gov/12684359/ source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Side effects included nausea during the first 2 weeks of treatment in two patients.”
§ The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis > Results > Weight Loss Outcomes
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Triglycerides (OR = 0.99; p < 0.05), ALT (OR = 0.87; p = 0.05), and AST (OR = 0.89; p < 0.05) at baseline were negatively associated with weight loss of at least 5% at 3 months’ follow-up (p < 0.05).”
§ The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis > Abstract > Results
plainstates an associationn = 38 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
30 more claims
Create a free account to see all 57 claims and to verify the 27 references still open.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After 6 months of weekly subcutaneous therapy with semaglutide at a maximum dose of 0.5 mg, an average total body weight loss of 10.3% was observed [24].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis > Abstract > Results
“ALT (OR = 0.87; p = 0.05)”
§ The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis > Results > Logistic Regression Analysis for Weight Loss of at Least 5% at 3 Months’ Follow-up
“| ALT [U/L] | 0.87 | 0.78–0.95 | 0.005** |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Age was 46.4 ± 8.8 years (mean ± SD), and 75.4% of patients were female.”
§ The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis > Results > Patient Characteristics at Baseline
Reported 75.4 · recomputed 72.727273
Citations
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 34 · Cited by 92
Research works printed but not linked: 1
- Dushay J, Eleftheria M;, Flier M, et al. Patterns and predictors of weight loss with exenatide treatment in overweight and obese women. medRxiv [Internet]. Cold Spring Harbor Laboratory Press; 2020 [cited 2021 Dec 28];2020.06.11.20128645. Available from: https://www.medrxiv.org/content/https://doi.org/10.1101/2020.06.11.20128645v1 · doi:10.1101/2020.06.11.20128645v1
Metadata
- Authors
- Lautenbach, A., Wernecke, M., Huber, T. B., Stoll, F., Wagner, J., Meyhöfer, S. M., Meyhöfer, S., & Aberle, J.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- German Center for Diabetes Research (DE)
- Corresponding author
- Lautenbach, Anne
- ORCID
- Venue
- Obesity Surgery
- Published
- 2022-07-25
- Volume
- 32
- Issue
- 10
- Pages
- 3280-3288
- ISSN
- 0960-8923 (ISSN-L)
- 1708-0428
- PMC
- PMC9532334
- OpenAlex
- W4287833463
- Cited by
- 92
- References
- 34
- Citations by year
- 2026: 19 · 2025: 33 · 2024: 23 · 2023: 15 · 2022: 2
- FWCI
- 17.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Obesity Surgery (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Universitätsklinikum Hamburg-Eppendorf (UKE)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Body Contouring and Surgery
- Keywords
- semaglutide, GLP-1 receptor agonists
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Semaglutide, C-Reactive Protein, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Lipids, Obesity, Morbid, Prospective Studies, Retrospective Studies, Triglycerides, Weight Gain, Weight Loss, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis. https://app.cochat.ai/papers/10.1007/s11695-022-06211-9
- The paper
- Lautenbach, A., Wernecke, M., Huber, T. B., Stoll, F., Wagner, J., Meyhöfer, S. M., Meyhöfer, S., & Aberle, J. (2022). The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis. Obesity Surgery. https://doi.org/10.1007/s11695-022-06211-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.